PUBLICATIONS
research progress by the beatty laboratory
Original Publications:
2021
TNF blockade uncouples toxicity from antitumor efficacy induced with CD40 chemoimmunotherapy. Stone ML, Lee J, Herrera VM, Graham K, Lee JW, Huffman A, Coho H, Tooker E, Myers MI, Giannone M, Li Y, Buckingham TH, Long KB, Beatty GL. JCI Insight. 2021 Jul 22;6(14):e146314.
Systemic inflammation is a determinant of outcomes of CD40 agonist-based therapy in pancreatic cancer patients. Wattenberg MM, Herrera VM, Giannone MA, Gladney WL, Carpenter EL, Beatty GL. JCI Insight. 2021 Mar 8;6(5):e145389.
A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma. Reiss KA, Wattenberg MM, Damjanov N, Prechtel Dunphy E, Jacobs-Small M, Lubas MJ, Robinson J, Dicicco L, Garcia-Marcano L, Giannone MA, Karasic TB, Furth EE, Carpenter EL, Wojcieszynski AP, Vonderheide RH, Beatty GL, Ben-Josef E. Mol Cancer Ther. 2021 Feb;20(2):389-397.
2020
Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. Ko AH, Jordan AC, Tooker E, Lacey SF, Chang RB, Li Y, Venook AP, Tempero M, Damon L, Fong L, O'Hara MH, Levine BL, Melenhorst JJ, Plesa G, June CH, Beatty GL. Mol Ther. 2020 Nov 4;28(11):2367-2378.
Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis. Lin JH, Huffman AP, Wattenberg MM, Walter DM, Carpenter EL, Feldser DM, Beatty GL, Furth EE, Vonderheide RH. J Exp Med. 2020 Aug 3;217(8):e20190673.
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Wattenberg MM, Asch D, Yu S, O'Dwyer PJ, Domchek SM, Nathanson KL, Rosen MA, Beatty GL, Siegelman ES, Reiss KA. Br J Cancer. 2020 Feb;122(3):333-339.
2019
Peripheral blood T cell fitness is diminished in patients with pancreatic carcinoma but can be improved with homeostatic cytokines. Xu J, Sai H, Li Y, Jordan AC, McGettigan SE, Chen JH, Bedoya F, Fraietta JA, Gladney WL, Melenhorst JJ, Beatty GL. Cell Mol Gastroenterol Hepatol. 2019 Aug 6.
Hepatocytes direct the formation of a pro-metastatic niche in the liver. Lee JW, Stone ML, Porrett PM, Thomas SK, Komar CA, Li JH, Delman D, Graham K, Gladney WL, Hua X, Black TA, Chien AL, Majmundar KS, Thompson JC, Yee SS, O'Hara MH, Aggarwal C, Xin D, Shaked A, Gao M, Liu D, Borad MJ, Ramanathan RK, Carpenter EL, Ji A, de Beer MC, de Beer FC, Webb NR, Beatty GL. Nature. 2019 Mar;567(7747):249-252.
Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47-mediated 'don't-eat-me' signal. Liu M, O'Connor RS, Trefely S, Graham K, Snyder NW, Beatty GL. Nat Immunol. 2019 Mar;20(3):265-275.
A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors. Beatty GL, Shahda S, Beck T, Uppal N, Cohen SJ, Donehower R, Gabayan AE, Assad A, Switzky J, Zhen H, Von Hoff DD. Oncologist. 2019 Jan;24(1):14-e10.
2018
CD38+ M-MDSC expansion characterizes a subset of advanced colorectal cancer patients. Karakasheva TA, Dominguez GA, Hashimoto A, Lin EW, Chiu C, Sasser K, Lee JW, Beatty GL, Gabrilovich DI, Rustgi AK. JCI Insight. 2018 Mar 22;3(6):e97022
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. Beatty GL, O'Hara MH, Lacey SF, Torigian DA, Nazimuddin F, Chen F, Kulikovskaya IM, Soulen MC, McGarvey M, Nelson AM, Gladney WL, Levine BL, Melenhorst JJ, Plesa G, June CH. Gastroenterology. 2018 Jul;155(1):29-32.
2017
CTLA-4/CD80 pathway regulates T cell infiltration into pancreatic cancer. Bengsch F, Knoblock DM, Liu A, McAllister F, Beatty GL. Cancer Immunol Immunother. 2017 Dec;66(12):1609-1617.
IL6 Receptor Blockade Enhances Chemotherapy Efficacy in Pancreatic Ductal Adenocarcinoma. Long KB, Tooker G, Tooker E, Luque SL, Lee JW, Pan X, Beatty GL. Mol Cancer Ther. 2017 Sep;16(9):1898-1908. doi: 10.1158/1535-7163.
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. Beatty GL, O'Dwyer PJ, Clark J, Shi JG, Bowman KJ, Scherle PA, Newton RC, Schaub R, Maleski J, Leopold L, Gajewski TF. Clin Cancer Res. 2017 Jul 1;23(13):3269-3276.
Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma. Kalbasi A, Komar C, Tooker GM, Liu M, Lee JW, Gladney WL, Ben-Josef E, Beatty GL. Clin Cancer Res. 2017 Jan 1;23(1):137-148.
2016
IFNγ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma. Long KB, Gladney WL, Tooker GM, Graham K, Fraietta JA, Beatty GL. Cancer Discov. 2016 Apr;6(4):400-413.
2015
Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages. Beatty GL, Winograd R, Evans RA, Long KB, Luque SL, Lee JW, Clendenin C, Gladney WL, Knoblock DM, Guirnalda PD, Vonderheide RH. Gastroenterology. 2015 Jul;149(1):201-10.
2014
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH. Cancer Immunol Res. 2014 Feb;2(2):112-20.
2013
A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH, O'Dwyer PJ. Clin Cancer Res. 2013 Nov 15;19(22):6286-95.
2011
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH. Science. 2011 Mar 25;331(6024):1612-6.
Select Reviews:
2021
Serum Amyloid A Proteins and Their Impact on Metastasis and Immune Biology in Cancer. Lee J, Beatty GL. Cancers (Basel). 2021 Jun 25;13(13):3179.
The biological underpinnings of therapeutic resistance in pancreatic cancer. Beatty GL, Werba G, Lyssiotis CA, Simeone DM. Genes Dev. 2021 Jul 1;35(13-14):940-962.
2020
The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance. Chang RB, Beatty GL. J Leukoc Biol. 2020 Jul;108(1):363-376.
Paracrine and cell autonomous signalling in pancreatic cancer progression and metastasis. Thomas SK, Lee J, Beatty GL. EBioMedicine. 2020 Mar;53:102662.
Inflammatory networks cultivate cancer cell metastasis to the liver. Lee JW, Beatty GL. Cell Cycle. 2020 Mar;19(6):642-651.
Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle. Wattenberg MM, Beatty GL. Semin Cancer Biol. 2020 Jan 15:S1044-579X(20)30003-1.
2019
Cellular determinants and therapeutic implications of inflammation in pancreatic cancer. Stone ML, Beatty GL. Pharmacol Ther. 2019 May 31. pii: S0163-7258(19)30094-4.
Broadening the impact of immunotherapy to pancreatic cancer: Challenges and opportunities. Balachandran VP, Beatty GL, Dougan SK. Gastroenterology. 2019 Jan 17.
2017
Deploying Immunotherapy in Pancreatic Cancer: Defining Mechanisms of Response and Resistance. Beatty GL, Eghbali S, Kim R. Am Soc Clin Oncol Educ Book. 2017;37:267-278.
Functio Laesa: Cancer Inflammation and Therapeutic Resistance. Liu M, Kalbasi A, Beatty GL. J Oncol Pract. 2017 Mar;13(3):173-180.
Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Beatty GL, Li Y, Long KB. Expert Rev Anticancer Ther. 2017 Feb;17(2):175-186.
2016
Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps. Beatty GL, O'Hara M. Pharmacol Ther. 2016 Oct;166:30-9.
Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (LSL-Kras(G12D/+) ;LSL-Trp53(R172H/+) ;Pdx-1-Cre), Its Variants, and Their Application in Immuno-oncology Drug Discovery. Lee JW, Komar CA, Bengsch F, Graham K, Beatty GL. Curr Protoc Pharmacol. 2016 Jun 1;73:14.39.1-14.39.20.
2015
Immune escape mechanisms as a guide for cancer immunotherapy. Beatty GL, Gladney WL. Clin Cancer Res. 2015 Feb 15;21(4):687-92. doi: 10.1158/1078-0432.
2013
Harnessing the antitumor potential of macrophages for cancer immunotherapy. Long KB, Beatty GL. Oncoimmunology. 2013 Dec 1;2(12):e26860.
